- Home
- CADL vs AQST Comparison
CADL vs AQST Comparison
Compare CADL & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CADL
- AQST
- Stock Information
- Founded
- CADL 1999
- AQST 2004
- Country
- CADL United States
- AQST United States
- Employees
- CADL N/A
- AQST N/A
- Industry
- CADL Biotechnology: Pharmaceutical Preparations
- AQST Biotechnology: Pharmaceutical Preparations
- Sector
- CADL Health Care
- AQST Health Care
- Exchange
- CADL Nasdaq
- AQST Nasdaq
- Market Cap
- CADL 234.8M
- AQST 272.9M
- IPO Year
- CADL 2021
- AQST 2018
- Fundamental
- Price
- CADL $5.45
- AQST $2.71
- Analyst Decision
- CADL Strong Buy
- AQST Strong Buy
- Analyst Count
- CADL 4
- AQST 5
- Target Price
- CADL $21.00
- AQST $11.40
- AVG Volume (30 Days)
- CADL 991.5K
- AQST 1.7M
- Earning Date
- CADL 05-13-2025
- AQST 05-12-2025
- Dividend Yield
- CADL N/A
- AQST N/A
- EPS Growth
- CADL N/A
- AQST N/A
- EPS
- CADL N/A
- AQST N/A
- Revenue
- CADL N/A
- AQST $54,228,000.00
- Revenue This Year
- CADL N/A
- AQST N/A
- Revenue Next Year
- CADL N/A
- AQST $40.62
- P/E Ratio
- CADL N/A
- AQST N/A
- Revenue Growth
- CADL N/A
- AQST 5.29
- 52 Week Low
- CADL $3.79
- AQST $2.12
- 52 Week High
- CADL $14.60
- AQST $5.80
- Technical
- Relative Strength Index (RSI)
- CADL 50.27
- AQST 54.01
- Support Level
- CADL $5.18
- AQST $2.22
- Resistance Level
- CADL $6.29
- AQST $2.79
- Average True Range (ATR)
- CADL 0.41
- AQST 0.19
- MACD
- CADL 0.08
- AQST 0.04
- Stochastic Oscillator
- CADL 42.89
- AQST 75.64
About CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.